🇺🇸 FDA
Pipeline program

Vabysmo 120 mg/mL solution for injection

MR45638

Approved small_molecule active

Quick answer

Vabysmo 120 mg/mL solution for injection for Neovascular Age-Related Macular Degeneration is a Approved program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

Program details

Company
Hoffmann-La Roche
Indication
Neovascular Age-Related Macular Degeneration
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials